Blopress

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Blopress

Quick Facts

Feature Detail
Active Ingredient Candesartan cilexetil
Drug Class Angiotensin II Receptor Blocker (ARB)
Primary Uses High blood pressure (hypertension), Heart failure
Administration Oral tablet, usually once daily

What is Blopress?

Blopress is a brand name for the medicine whose active ingredient is candesartan cilexetil. It belongs to a class of medications called Angiotensin II Receptor Blockers (ARBs).

How it Works

Candesartan cilexetil is a prodrug, meaning it is inactive until the body metabolizes it into its active form, candesartan, during absorption in the gastrointestinal tract. Candesartan works by blocking the action of a naturally occurring substance called angiotensin II at specific receptors in the body (the AT1 receptors). Angiotensin II typically causes blood vessels to narrow (vasoconstriction) and promotes the retention of sodium and water. By blocking these effects, candesartan causes blood vessels to relax and widen, which in turn helps to lower blood pressure and makes it easier for the heart to pump blood throughout the body.

Therapeutic Indications

Blopress is primarily indicated for:

  • The treatment of essential hypertension (high blood pressure) in adults, children, and adolescents (aged 6 to less than 18 years).
  • The treatment of heart failure in adult patients with reduced heart muscle function. It may be used alone or in combination with other heart failure medications.

Regulatory References

  1. angiotensin II
  2. essential hypertension
  3. heart failure

What side effects are possible with Blopress ?

Possible Side Effects and Safety Information

The safety profile of Blopress (candesartan cilexetil) is based on adverse reactions categorized by frequency and system-organ class, as documented in regulatory filings. The most frequently observed adverse reactions are classified as common in official documents, including headache, dizziness, and hypotension (low blood pressure).


Frequency-Classified Adverse Reactions

Adverse effects are formally categorized based on incidence rates:

  • Common: Headache, Dizziness, Hypotension, Hyperkalaemia (elevated potassium levels), Renal impairment.
  • Very Rare: Agranulocytosis, Leukopenia (blood disorders); Hepatitis (liver function disorders); Angioedema (swelling of the face or throat), Rash, Urticaria.

System-Organ-Class Groupings

Side effects are also grouped by the body systems affected, according to regulatory standards, including Blood and lymphatic system disorders, Nervous system disorders, Vascular disorders, Hepatobiliary disorders, and Renal and urinary disorders.

Serious Safety Considerations

Serious adverse reactions documented in regulatory sources include Angioedema, Severe Hypotension, and potentially life-threatening Blood Dyscrasias. The official safety documents contain specific constraints regarding use.

Population-Specific Safety

Official labeling states that Blopress is contraindicated in pregnancy during the second and third trimesters due to the risk of fetal injury or death. Use is also restricted in patients with severe hepatic impairment and in children under 1 year of age. Furthermore, hypotension is noted to be more likely at the start of treatment or during dose increases, particularly in volume-depleted patients, as an exposure-related safety pattern documented in regulatory texts. The co-administration with other RAAS inhibitors (e.g., ACE inhibitors) is restricted due to an increased risk of hypotension, hyperkalaemia, and decreased renal function.

Overdose and Emergency Response

The regulatory guidance for an overdose of Blopress (candesartan cilexetil) focuses on the physiological consequences of an intensified drug effect and the resulting mandated emergency response.

The primary manifestation documented in official regulatory profiles is symptomatic hypotension (severe low blood pressure) and associated signs such as dizziness. An overdose is considered a serious event, with the core risk being profound hypotension leading to potential circulatory compromise. Other documented presentations may include a fast or slow heartbeat.

Overdose Status Official Regulatory Statements
Emergency Action Seek emergency medical attention immediately. Call emergency services or a Poison Help line.
Antidote No specific antidote is known for candesartan cilexetil overdose.
Management Management relies on symptomatic and supportive treatment. Procedures such as gastric lavage or administration of activated charcoal may be considered if ingestion was recent. Treatment for severe hypotension may involve the use of intravenous fluids and vasopressors.
Special Consideration Candesartan cannot be removed by hemodialysis due to its high degree of plasma protein binding, a critical fact for clinical management.

The regulatory profile explicitly mandates urgent medical intervention due to the severity of potential hypotension. Since no specific antidote is known, official procedures are limited to supportive care and intensive monitoring until vital signs are stable.

Therapeutic Uses of Blopress

What Blopress Treats: Main Uses and Benefits

Blopress (candesartan) is applied across therapeutic domains where additional symptomatic support is needed to maintain cardiovascular stability. This medication is relevant in contexts marked by increased discomfort or tension related to systemic imbalance.


Managing High Blood Pressure and Heart Failure

This medication is commonly used to help with conditions presenting with significant symptomatic burden related to hypertension (high blood pressure) and heart failure. It assists with maintaining functional stability by managing symptoms related to heightened physiological activity. Blopress is applied in clinical settings that involve acute or unstable symptom patterns, supporting the patient during difficult episodes by easing distress.

The primary therapeutic uses include supportive management for conditions involving episodic or fluctuating manifestations such as hypertension and heart failure where functional stability becomes affected. This contributes to easing the overall symptom load and supports general well-being during symptomatic phases.


Addressing Cardiovascular Strain

The medication is considered relevant for easing symptoms that create noticeable physiological strain and may occur during flare-ups. This provides supportive relief that helps patients cope more steadily with difficult episodes.

Quick Fact: Relief for Physiological Strain

Eligibility and Restrictions for Use

The eligibility rules for using Blopress (candesartan cilexetil) are strictly defined by regulatory authorities and based on specific population categories and medical conditions.


Contraindicated Populations

Use of this medicine is strictly prohibited (contraindicated) for several groups. This includes women in the second and third trimesters of pregnancy. Patients must also not use Blopress if they have severe hepatic impairment or cholestasis, a documented hypersensitivity to any component, or if they have diabetes mellitus and are also taking a medicine containing aliskiren. Additionally, the medicine is contraindicated for the treatment of hypertension in infants less than one year of age.


Eligibility and Restrictions

Blopress is approved for use in adults for both hypertension and heart failure. For hypertension, it is also approved for use in children and adolescents generally aged one year and older. Use is restricted in patients with certain conditions, such as moderate hepatic insufficiency or those who are volume-depleted, where special consideration is required upon initiation. The medicine is generally not recommended for patients, especially children, with severe renal impairment ( GFR < 30 mL/min/1.73m^2). Lactating mothers must discontinue either the drug or nursing.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Regulatory documentation outlines specific interaction patterns for Blopress (candesartan cilexetil), focusing primarily on pharmacodynamic effects and a limited metabolic profile.


Documented Interaction Patterns

Interacting Substance/Class Official Regulatory Statement
Aliskiren Co-administration is formally contraindicated in patients with diabetes mellitus or moderate-to-severe renal impairment.
ACE Inhibitors (e.g., lisinopril) Associated with increased risks of hypotension, hyperkalemia, and decreased renal function (dual RAS blockade).
NSAIDs Documented to potentially cause deterioration of renal function and attenuation of the antihypertensive effect, particularly in elderly or volume-depleted patients.
Potassium-Elevating Agents Co-use with Potassium supplements or Potassium-sparing diuretics is documented to increase the risk of hyperkalemia.
Lithium Co-administration is associated with a documented increase in serum lithium concentrations and toxicity, requiring necessary monitoring.

Metabolic and Food Interactions

Candesartan is eliminated to a minor extent by the CYP2C9 enzyme. Regulatory data indicate that Blopress has no expected or clinically relevant pharmacokinetic interactions with drugs that are metabolized by or affect the CYP450 enzyme system (such as CYP3A4). The bioavailability of candesartan is officially documented as not being affected by food.

Mechanism of Action

Blopress functions as an angiotensin II receptor blocker (ARB). Its mechanism involves selective binding to the AT1 receptor, a transmembrane protein expressed widely throughout the cardiovascular system, including on vascular smooth muscle cells and the adrenal glands.

The antagonism of the AT1 receptor prevents the endogenous ligand, Angiotensin II, from initiating its typical intracellular signaling cascade. This blockade inhibits receptor-mediated effects, primarily resulting in the suppression of vasoconstriction and the reduction of aldosterone secretion.

The inhibition of vasoconstriction and aldosterone release modulates the renin-angiotensin-aldosterone system (RAAS). This modulation results in a reduction in systemic vascular resistance and a decrease in the extracellular fluid volume.

Dosage and Administration Information

Instruction Map: How to use Blopress — Administration Guidelines

This map details the administration instructions for Blopress (candesartan cilexetil) and describes the standard usage patterns.


Administration Scope

Feature Detail
Route of administration Oral administration only, primarily as a tablet.
Dosing schedule Adult Hypertension: Usual starting dose is 16 mg once daily, with a maximum dose of 32 mg daily. Adult Heart Failure: Starting dose is 4 mg once daily, with a target dose of 32 mg once daily.
Timing in relation to meals (if applicable) May be taken with or without food.
Preparation requirements (if applicable) An oral suspension may be prepared from the tablets for patients who require non-tablet administration, such as younger children.
Age-group administration rules Population Adjustments: A lower initial dose (4 mg or 8 mg) should be considered for patients with severe renal impairment or moderate hepatic impairment. Pediatric Use (6 to <18 years): Dosing is adjusted based on body weight.
Missed-dose rules If a dose is missed, the standard procedure is to skip the missed dose and take the next scheduled dose at the regular time, rather than taking a double dose.
Special procedural conditions The medication should be taken at approximately the same time each day to maintain consistent drug levels. Tablets in certain strengths may be scored for dividing.

Instruction Classifications (High-Level)

Classification Detail
Administration method type Oral (tablet or prepared suspension)
Frequency pattern Once daily (continuous, long-term use)
Basis Standard therapeutic protocols
Use-context constraints Requires dose titration for heart failure; requires initial dose reduction for specific patient groups.

Resulting Procedural Structure

Standard step sequence:

  • The starting dose is determined based on the condition being treated and the presence of any pre-existing conditions, such as severe renal impairment.
  • The medication is administered orally, once daily, ensuring consistency in the time of day the dose is taken.
  • For heart failure, the dose is systematically doubled at intervals of at least two weeks until the target dose of 32 mg is reached, or the highest dose tolerated.
  • If a dose is missed, it is specified not to take a double dose to compensate.

Connection to the Overall Use Protocol

The instructions define a standardized once-daily oral intake for Blopress, establishing different starting doses for hypertension (16 mg) versus heart failure (4 mg). This framework involves a structured titration process for heart failure and requires a defined reduction in the initial dose for specific patient populations, such as those with impaired renal or hepatic function.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Blopress

Evidence for Use in Essential Hypertension (High Blood Pressure)

Research examining candesartan (Blopress) for high blood pressure primarily involved Randomized Controlled Trials (RCTs). These studies monitored key outcomes monitoring physiological strain or stress, such as changes in both systolic and diastolic blood pressure measurements. Researchers also examined whether these trials showed specific patterns observed in the studies regarding long-term cardiovascular outcomes, such as the occurrence of stroke, particularly in high-risk populations.

Studies were conducted to examine how outcomes related to systemic or functional imbalance evolved across the observed patient populations during the study period. Evidence contributes to understanding how blood pressure patterns evolved in the observed populations.

Evidence for Use in Chronic Heart Failure

Research exploring candesartan for chronic heart failure centered on large-scale, international Randomized Controlled Trial programs. These programs included trials with different patient populations, such as those who were tolerant of or unable to tolerate other standard heart failure therapies. The primary focus of these studies was to monitor composite measures tracking specific severe cardiovascular events, which are outcomes related to systemic or functional imbalance.

The main trial program reported how symptoms evolved in the observed populations over a median follow-up of over three years in patients with reduced heart muscle function (reduced LVEF). In the trial component focusing on patients with preserved function, the reported pattern for the primary composite outcome did not meet the pre-specified statistical threshold for distinction from the inactive substance. Study discontinuation was observed more frequently in the candesartan group compared to the placebo group.

What Remains Unclear or Under-Studied

This summary highlights several areas where clinical evidence is still developing or remains limited. For patients with heart failure who have a preserved LVEF, the evidence structure from the main clinical trials is less consistent, meaning certainty remains low in this specific context. Data for certain groups remain insufficient, specifically for children and adolescents regarding heart failure. Furthermore, follow-up durations were limited in some hypertension studies, meaning research exploring very long-term outcomes and durability is still developing. Research highlights that the reported pattern of blood pressure change in Black patients may be less pronounced, indicating a difference in observed group patterns. Comparative evidence is lacking for some combinations of existing heart failure therapies.

Frequently Asked Questions (FAQ)

Common questions about Blopress (FAQ)


Q: How is Blopress different from other blood pressure medications like ACE inhibitors?

A: Blopress belongs to a class called Angiotensin II Receptor Blockers (ARBs). ARBs work by blocking a receptor (AT1) where Angiotensin II acts. This differs from ACE inhibitors, which work by preventing the formation of Angiotensin II. Regulatory documents caution that combining ARBs and ACE inhibitors is associated with an increased risk of side effects like low blood pressure and high potassium.

Q: How quickly should I expect Blopress to start working after I take it?

A: The official product information indicates that Blopress is intended for long-term management. The majority of the blood pressure-lowering effect is typically observed within approximately four weeks of beginning treatment.

Q: Does Blopress need to be taken at a specific time of day?

A: Official administration guidelines state that the medication should be taken at approximately the same time each day to support consistent drug levels.

Q: What kind of monitoring is typically done when a person starts Blopress?

A: Due to the documented potential for effects on potassium levels and kidney function, official product information indicates that these factors are typically subject to monitoring, particularly when treatment is started or when a change is made to the dose.

Q: Is it common to feel dizzy or lightheaded when starting Blopress?

A: Regulatory documents list dizziness and hypotension (low blood pressure) as common adverse reactions. Low blood pressure is noted to be more likely when treatment first begins or when the dose is increased, especially for populations that may be volume-depleted.

Q: Can Blopress cause tiredness or fatigue?

A: Official documentation from some regulatory bodies lists sleepiness and a general feeling of tiredness or weakness among the less common adverse reactions associated with the medicine. Tiredness or fatigue are documented as possible effects.

Q: Can Blopress be taken with common cold and flu medications?

A: Regulatory warnings mention a potential interaction with NSAIDs (Non-Steroidal Anti-Inflammatory Drugs), which are ingredients found in some common cold and flu products. This co-use is documented to potentially reduce the blood pressure-lowering effect and may cause deterioration of kidney function.

Q: Does Blopress have a generic version available?

A: Yes. The active ingredient in Blopress is candesartan cilexetil, which is widely available as a generic medicine in many regions.

Q: Can I drink coffee or tea while taking Blopress?

A: Official regulatory data on the medicine states that its effectiveness is not affected by food. There are no specific restrictions against drinking coffee or tea documented in the product labeling.

Q: Are there any specific foods I should avoid when using Blopress?

A: While there are no general food restrictions, official health information emphasizes caution regarding potassium-rich salt substitutes. Official documentation notes that the co-use of Blopress and potassium-rich salt substitutes is associated with an increased risk of high potassium levels (hyperkalemia) in the blood.

Q: Can Blopress affect kidney function?

A: Official documents list renal impairment (changes to kidney function) as a common adverse reaction. The product information also notes that dose adjustments or monitoring may be needed for patients with pre-existing severe kidney impairment.

Q: Does Blopress interact with common pain relievers like ibuprofen?

A: Regulatory documentation specifically states that NSAIDs (Non-Steroidal Anti-Inflammatory Drugs), such as ibuprofen, may interact with Blopress. This interaction is documented as potentially causing deterioration of kidney function and reducing the medicine’s ability to lower blood pressure.

Q: Is Blopress known to interact with alcohol?

A: Public health agencies note that consuming alcohol may increase the blood pressure-lowering effect of the medicine. This may be associated with an increased possibility of experiencing effects like dizziness or lightheadedness.

Q: Does Blopress affect heart rate?

A: Official documentation from some regions lists heart-related symptoms, such as palpitation and bradycardia (a slow heart rate), as possible undesirable effects associated with the drug.

Q: Can Blopress cause sexual side effects?

A: Sexual side effects are not explicitly listed as common adverse reactions in the main regulatory documents. However, official safety documentation sometimes includes related conditions under general body system disorders.

Q: Is it necessary to avoid grapefruit when taking Blopress?

A: Official regulatory documents indicate that the metabolism of the active ingredient is not expected to have clinically relevant interactions with the enzyme system affected by grapefruit. No general restriction on grapefruit is stated in the product labeling.

Q: Does Blopress cause weight gain or weight loss?

A: Official documentation from some regulatory bodies lists weight gain in the incidence-not-known or less common categories of adverse reactions. This is not listed as a common effect in major regulatory documents.

Q: Is it true that Blopress can cause a dry cough?

A: Blopress belongs to the ARB class of medications. Regulatory-adjacent information on the ARB class indicates that these drugs generally do not cause the persistent dry cough commonly associated with the ACE inhibitor class.

Q: Is Blopress prescribed for conditions other than high blood pressure and heart failure?

A: Official therapeutic indications, which define the approved uses of the drug, are strictly limited to the treatment of essential hypertension (high blood pressure) and chronic heart failure.

Q: Is it normal to have swelling in the hands or feet while on Blopress?

A: While a serious, very rare adverse effect called angioedema (swelling of the face or throat) is documented, some official documentation also lists general swelling of the hands or feet (peripheral edema) as a less common symptom associated with the drug.

Q: Does Blopress lose its effectiveness over time?

A: Official regulatory-based research, including studies lasting up to 12 months, indicates that the medicine maintains its blood pressure-lowering effects and tolerability during long-term administration.

Q: Can Blopress affect sleep or cause insomnia?

A: Official documentation from some regulatory bodies lists both insomnia (difficulty sleeping) and sleepiness as possible undesirable effects associated with Blopress.

Q: Can Blopress interact with herbal products?

A: Public health agencies note that there is generally limited information on taking herbal remedies and supplements with prescription medicines like Blopress, as they are not typically tested together.

Q: Are there restrictions on driving or operating machinery while on Blopress?

A: Official labeling advises that the medicine can sometimes affect alertness or coordination, particularly if dizziness occurs. Official labeling advises against driving or performing activities requiring alertness until a user understands how the medicine may affect them.

Q: Are there known genetic factors that affect how Blopress works?

A: Regulatory documents note that the blood pressure-lowering effect was observed to be somewhat less pronounced in certain groups, such as Black patients, which is generally recognized for the ARB class of medications.

Q: What evidence exists for Blopress reducing cardiovascular risk?

A: Large-scale clinical trial programs, notably the CHARM studies, were conducted to examine the effect of Blopress. The reported findings tracked how the use of the medicine, compared to an inactive substance, affected the rates of cardiovascular mortality and hospitalizations due to heart failure.

How should Blopress be stored and disposed of?

How to Store and Dispose of Blopress

The official labeling outlines specific conditions for storage and disposal to maintain product integrity and ensure safety.


Storage Requirements

Blopress (candesartan cilexetil) must be stored at room temperature, which is typically defined as away from excess heat and moisture. To protect the tablets from environmental factors, it is required that the medicine be kept in its original container and that the container remains tightly closed.

Crucially, all medication must be stored out of the sight and reach of children.


Disposal Instructions

To dispose of unused or expired Blopress, do not throw the medicine away via wastewater or household waste. Instead, regulatory bodies instruct patients to ask a pharmacist or utilize an official drug take-back program. These controlled disposal methods help protect the environment and prevent accidental exposure.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Blopress  found in:

A-Z Index: